Solid Tumor, Adult Clinical Trial
Official title:
A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
Verified date | March 2020 |
Source | CStone Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, open label, dose escalation & expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.
Status | Completed |
Enrollment | 18 |
Est. completion date | June 18, 2020 |
Est. primary completion date | June 18, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subjects with histologically or cytologically confirmed advanced or metastatic solid tumor(s) for which no effective standard therapy is available or tolerable. 2. ECOG performance status of 0 or 1. 3. Life expectancy =12 weeks. 4. Able to swallow and retain oral medication. 5. Subjects must have adequate organ function. 6. Use of effective contraception. Exclusion Criteria: 1. Subjects receiving anti-cancer therapy at the time of enrollment. 2. Subjects who had prior chemotherapy, targeted therapy, immunotherapy or any other systemic anti-cancer treatment, within 14 days prior to the first dose of CS3006 or who has not recovered from adverse events due to a prior therapy. 3. Receipt of any prior therapy with a MEK inhibitor. 4. Use of any investigational anti-cancer drug within 28 days before the first dose of CS3006. 5. Current use of a prohibited medication or use during treatment of CS3006. 6. Current use of warfarin. 7. Any condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs. 8. History of retinal vein occlusion (RVO) or central serous retinopathy (CSR). 9. Visible retinal pathology as assessed by ophthalmologic exam. 10. Intraocular pressure > 21mm Hg as measured by tomography. 11. Glaucoma diagnosed within one month prior to the first dose of CS3006. 12. Known brain metastasis or other CNS metastasis that is either symptomatic or untreated. 13. Primary malignancy of CNS. 14. Evidence of severe or uncontrolled systemic diseases. 15. Subjects with clinically significant cardiovascular disease. 16. QTc interval >= 450 msecs for male or >= 470 msecs for female 17. Known history of HIV. 18. Subjects with active Hepatitis B or C infection 19. History of immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to CS3006. For more information regarding trial participation, please contact at cstonera@cstonepharma.com |
Country | Name | City | State |
---|---|---|---|
Australia | St Vincent's hospital | Sydney | New South Wales |
Lead Sponsor | Collaborator |
---|---|
CStone Pharmaceuticals |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with adverse events | From the day of first dose to 30 days after last dose of CS3006 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04551885 -
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05054348 -
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088004 -
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT04020185 -
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05071846 -
MVX-ONCO-2 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05607199 -
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
|
Phase 1 | |
Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
Active, not recruiting |
NCT06026254 -
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
|
Phase 1 | |
Recruiting |
NCT06032845 -
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)
|
Phase 2 | |
Recruiting |
NCT06144671 -
GT201 Injection For The Treatment Of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05276284 -
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04121442 -
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04221204 -
A Monotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03992326 -
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05435339 -
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
Recruiting |
NCT06075849 -
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
|
Phase 1 | |
Recruiting |
NCT04092673 -
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
|
Phase 1/Phase 2 |